Skin directed therapy for mycosis fungoides: A review

Journal of Drugs in Dermatology

Volumn 7, Issue 7, 2008, Pages 655-666

  Berthelot, Cindy ^a   Rivera, Allison ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCINEURIN; CORTICOSTEROID; PHOTOSENSITIZING AGENT; RETINOID;

DRUG ANTAGONISM; EXCIMER LASER; HUMAN; MULTIMODALITY CANCER THERAPY; MYCOSIS FUNGOIDES; PATHOLOGY; PHOTOCHEMOTHERAPY; REVIEW; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; CALCINEURIN; COMBINED MODALITY THERAPY; HUMANS; LASERS, EXCIMER; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RETINOIDS; SKIN NEOPLASMS;

EID: 52449090696     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007; 143:854-859.
2. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240-1244. (Pubitemid 29359582)
3. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA. 1988;260:42-46.
4. Kikuchi A, Ohata Y, Matsumoto H, et al. Anti-HTLV-1 antibody positive cutaneous T-cell lymphoma. Cancer. 1997;79:269-274. (Pubitemid 27029891)
5. Pancake BA, Wassef EH, Zucker-Franklin D. Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus. Blood. 1996;88:3004-3009. (Pubitemid 26357382)
6. Pancake BA, Zucker-Franklin D, Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. J Clin Invest. 1995;95:547-554.
7. Pawson R, Catovsky D, Schulz TF. Lack of evidence of HHV-8 in mature T-cell lymphoproliferative disorders. Lancet. 1996;348: 1450-1451. (Pubitemid 26395250)
8. Sander CA, Simon M, Puchta U, et al. HHV-8 in lymphoproliferative lesions in skin. Lancet. 1996;348:475-476.
9. Tuyp E, Burgoyne A, Aitchison T, et al. A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol. 1987;123:196-200. (Pubitemid 17002488)
10. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a casecontrol study. J Natl Cancer Inst. 1989;81:1560-1567. (Pubitemid 19253304)
11. Wood GS, Schaffer JM, Boni R, et al. No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma. Am J Pathol. 1997;150:667-673. (Pubitemid 27073793)
12. Zucker-Franklin D. The role of human T cell lymphotropic virus type I tax in the development of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:86-96. (Pubitemid 32928336)
13. Dereure O, Levi E, Vonderheid EC, et al. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol. 2002;118:949-956. (Pubitemid 34639172)
14. van Doorn R, Dijkman R, Vermeer MH, et al. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 2002;62:5389-5392.
15. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002; 46:95-106. (Pubitemid 34073484)
16. Fung MA, Murphy MJ, Hoss DM et al. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol. 2002; 46:325-357. (Pubitemid 34228882)
17. Alibert JLM. Description des maladies de la peau Observees a l'Hospital St Louis, Paris, France. Barrois L'aine et Fils. 1806;413-446.
18. Nashan D, Faulhaber D, Ständer S, et al. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156:1-10. (Pubitemid 44924138)
19. Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:943-960.
20. Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000; 18:2908-2925. (Pubitemid 30620080)
21. Kinney MC, Jones D. Cutaneous T-cell and NK-cell lymphomas: the WHO-EORTC classification and the increasing recognition of specialized tumor types. Am J Clin Pathol. 2007;127:670-686.
22. Weinstock MA, Horm JW. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer. 1988;62:1658-1661.
23. Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer. 1981;47:2671-2677. (Pubitemid 11113734)
24. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135:26-32. (Pubitemid 29069513)
25. Lamberg SI, Green SB, Byar DP, et al. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med. 1984;100:187-192. (Pubitemid 14188767)
26. Marti RM, Estrach T, Reverter JC, et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol. 1991; 127:1511-1516.
27. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med. 1988;109:372-382.
28. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784-1790. (Pubitemid 20015571)
29. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999;40:418-425. (Pubitemid 29115302)
30. Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132:1309-1313. (Pubitemid 26386618)
31. van Doorn R, Van Haselen CW, Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504-510. (Pubitemid 30212962)
32. Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol. 1998;39:S139-S143. (Pubitemid 28485164)
33. Duvic M, Olsen EA, Omura GA, et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001;44:940-947. (Pubitemid 32493443)
34. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci. 2002; 966:108-118. (Pubitemid 34729167)
35. Schwartzman RA, Cidlowski JA. Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol. 1994;105:347-354. (Pubitemid 24365644)
36. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336:1066-1071. (Pubitemid 27163860)
37. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498. (Pubitemid 32917240)
38. Zackheim HS. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol. 2003;42:53-56.
39. Farber EM, Zackheim HS, McClintock RP, et al. Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream. Arch Dermatol. 1968;97:165-172.
40. Cohen, H, Baer, R. Observations upon the use of topical triamcinolone acetonide preparations in various concentrations. Dermatologica. 1961;122:116-119.
41. Farber EM, Cox AJ, Steinberg J, et al. Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing. Cancer. 1966;19:237-245.
42. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134:949-954. (Pubitemid 28385316)
43. Harrison A, Duvic M. Diagnosis and treatment of Sézary syndrome. The Internet Journal of Dermatology. 2004;2.
44. Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician. 1990;41:1531-1538. (Pubitemid 20175844)
45. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581-588.
46. Marks R. Tinea incognito. Int J Dermatol. 1978;17:301-302. (Pubitemid 8360683)
47. Inoue Y, Isobe M, Shiohara T, et al. Inhibitory activity of CX- 659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses. Int Arch Allergy Immunol. 2003;131:143-152. (Pubitemid 36735217)
48. Bromberg JS. Adrenal insufficiency. N Engl J Med. 1997;336:1105-1107.
49. Walsh P, Aeling JL, Huff L, et al. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29:501-503. (Pubitemid 23260151)
50. Zackheim HS, Farber EM. Topical antimetabolites. Annu Rev Med. 1970;21:59-66.
51. Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q. 1983;50:91-95. (Pubitemid 14233633)
52. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995; 9:1031-1056.
53. Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology. 1999;199:102-105. (Pubitemid 29494782)
54. Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165-173. (Pubitemid 36216254)
55. Hoppe RT, Abel EA, Deneau DG, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987; 5:1796-1803. (Pubitemid 18023396)
56. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19:684-691.
57. Hamminga L, Hermans J, Noordijk EM, et al. Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients. Br J Dermatol. 1982;107:145-155. (Pubitemid 12041533)
58. Vonderheid EC, Van Scott EJ, Johnson WC, et al. Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate- term results. Arch Dermatol. 1977;113:454-462. (Pubitemid 8071605)
59. Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120:1585-1590. (Pubitemid 15176041)
60. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20:416-428. (Pubitemid 19086776)
61. Vonderheid EC, Van Scott EJ, Wallner PE, et al. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep. 1979;63:681-689. (Pubitemid 9217598)
62. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;49:35-49. (Pubitemid 36801629)
63. Grekin DA, Zackheim HS, Epstein EH, Jr. Topical chemotherapy of mycosis fungoides. Cutis. 1979;24:543-546.
64. Estève E, Bagot M, Joly P, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol. 1999;135:1349-1353.
65. Daughters D, Zackheim H, Maibach H. Urticaria and anaphylactoid reactions after topical application of mechlorethamine. Arch Dermatol. 1973;107:429-430.
66. Vonderheid EC. Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides. Int J Dermatol. 1984; 23:180-186. (Pubitemid 14172209)
67. Zackheim HS. Treatment of mycosis fungoides with topical nitrosourea compounds. Arch Dermatol. 1972;106:177-182.
68. Zackheim HS, Epstein EH, Jr. Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. Arch Dermatol. 1975;111:1564-1570.
69. Zackheim HS, Epstein EH, Jr., McNutt NS, et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10- year experience. J Am Acad Dermatol. 1983;9:363-374. (Pubitemid 13051877)
70. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22:802-810. (Pubitemid 20154080)
71. Thomson KF, Sheehan-Dare RA, Wilkinson SM. Allergic contact dermatitis from topical carmustine. Contact Dermatitis. 2000; 42:112. (Pubitemid 30077126)
72. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin. 2000;18:147-156. (Pubitemid 30013735)
73. Zackheim HS, Feldmann RJ, Lindsay C et al. Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. Br J Dermatol. 1977;97:65-67. (Pubitemid 8147986)
74. Petkovich PM. Retinoic acid metabolism. J Am Acad Dermatol. 2001;45:S136-S142. (Pubitemid 33032592)
75. Cheng SX, Kupper T. A new rexinoid for cutaneous t-cell lymphoma. Arch Dermatol. 2001;137:649-652. (Pubitemid 32458447)
76. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol. 1997; 37:S12-S17. (Pubitemid 27349989)
77. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37:S18-S24. (Pubitemid 27349990)
78. Mrass P, Rendl M, Mildner M, et al. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res. 2004;64:6542-6548. (Pubitemid 39297912)
79. Landthaler M, Kummermehr J, Wagner A, et al. Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Arch Dermatol Res. 1980;269:297-309. (Pubitemid 11207099)
80. Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs. 2000;1:514-523. (Pubitemid 32014100)
81. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325-332. (Pubitemid 34226330)
82. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002;8:1234-1240. (Pubitemid 34517663)
83. Smit JV, de Jong EM, van Hooijdonk CA, et al. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol. 2004;51:257-264.
84. Magliocco MA, Pandya K, Dombrovskiy V, et al. A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2006;54:115-118. (Pubitemid 41832467)
85. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206:142-147. (Pubitemid 36205282)
86. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol. 2004;150:545-553. (Pubitemid 38446312)
87. Cohen MH, Hirschfeld S, Flamm HS, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist. 2001;6:4-11. (Pubitemid 32155810)
88. Liu HL, Kim YH. Bexarotene gel: a Food and Drug Administration- approved skin-directed therapy for early-stage cutaneous Tcell lymphoma. Arch Dermatol. 2002;138:398-399. (Pubitemid 34226340)
89. Kuzel T, Breneman D, Duvic M, et al. Phase I-II trial of Targretin gel in the topical treatment of patients with cutaneous T-cell lymphoma. J Invest Dermatol. 2003;114:839.
90. Lain T, Talpur R, Duvic M. Long-term control of mycosis fungoides of the hands with topical bexarotene. Int J Dermatol. 2003; 42:238-241. (Pubitemid 41709837)
91. Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49:801-815. (Pubitemid 37314867)
92. Martin AG. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. J Drugs Dermatol. 2003;2: 155-167.
93. Apisarnthanarax N, Duvic M. Therapy options in cutaneous Tcell lymphoma. Expert Rev Anticancer Ther. 2001;1:403-420. (Pubitemid 34679432)
94. Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003;121:902-909. (Pubitemid 37239137)
95. Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50:600-607. (Pubitemid 38393171)
96. Marks R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol. 1997;37:S25-S32. (Pubitemid 27349991)
97. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol. 1998;134:57-60. (Pubitemid 28087114)
98. Sefton J, Kligman AM, Kopper SC et al. Photodamage pilot study: a double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel. J Am Acad Dermatol. 2000; 43:656-663.
99. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3:193-215. (Pubitemid 34533779)
100. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double- blind, vehicle-controlled study. Cutis. 1999;63:349-354.
101. Weinstein GD. Tazarotene gel: efficacy and safety in plaque psoriasis. J Am Acad Dermatol. 1997;37:S33-S38. (Pubitemid 27349992)
102. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760-767. (Pubitemid 36583288)
103. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol. 2000;136:1461-1469. (Pubitemid 32010747)
104. Bassiri-Tehrani S, BA BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol. 2002;41: 104-106. (Pubitemid 34552358)
105. Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol. 2004;13: 426-434. (Pubitemid 39077310)
106. Zackheim HS, Epstein EH Jr. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol. 1989;21:757-762.
107. Schappell DL, Alper JC, McDonald CJ. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermatol. 1995;131:307-313.
108. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol. 1996;34:626-631. (Pubitemid 26098012)
109. Bunn PA, Jr., Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994;121:592-602.
110. Argyropoulos CL, Lamberg SI, Clendenning WE, et al. Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides. Cancer Treat Rep. 1979; 63:619-621. (Pubitemid 9217586)
111. Chatterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res. 1997;14:1058-1065. (Pubitemid 27371407)
112. Wester RC, Melendres J, Sedik L, et al. Percutaneous absorption of azone following single and multiple doses to human volunteers. J Pharm Sci. 1994;83:124-125. (Pubitemid 24224163)
113. Demierre MF, Vachon L, Ho V, et al. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol. 2003; 139:624-628. (Pubitemid 36576378)
114. Sutton L, Swinehart JM, Cato A, et al. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol. 2001;40:464-467. (Pubitemid 32982303)
115. Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol. 1989;125:227-230. (Pubitemid 19070209)
116. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46:228-241. (Pubitemid 34118380)
117. Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol. 2003; 13:331-342. (Pubitemid 36963090)
118. Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician. 2002;66:1899-1902.
119. Hauk PJ, Leung DY. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol. 2001;107:391-392. (Pubitemid 32173922)
120. Pournaras CC, Lübbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol. 2001;116:480-481. (Pubitemid 32202922)
121. Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001;107:196-197. (Pubitemid 32105267)
122. Lazarous MC, Kerdel FA. Topical tacrolimus protopic. Drugs Today (Barc). 2002;38:7-15.
123. Rallis E, Economidi A, Verros C, Papadakis P. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol. 2006;5:906-907.
124. Pearson GW, Langley RG. Topical imiquimod. J Dermatolog Treat. 2001;12:37-40.
125. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol. 2002;147:1-6. (Pubitemid 34779430)
126. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:S6-S11. (Pubitemid 30447906)
127. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14. (Pubitemid 29097684)
128. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141. (Pubitemid 30195986)
129. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200. (Pubitemid 34141451)
130. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-1149. (Pubitemid 37045392)
131. Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol. 2003; 149 (Suppl):9-14.
132. Sullivan TP, Dearaujo T, Vincek V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003;29:1181-1186. (Pubitemid 38009915)
133. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 2002;138: 1137-1139. (Pubitemid 35025683)
134. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52:275-280.
135. Ariffin N, Khorshid M. Treatment of mycosis fungoides with imiquimod 5% cream. Clin Exp Dermatol. 2006;31:822-823. (Pubitemid 44563408)
136. Chong A, Loo WJ, Banney L, Grant JW, Norris PG. Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. J Dermatolog Treat. 2004;15:118-119. (Pubitemid 38477950)
137. Chiam LY, Chan YC. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Br J Dermatol. 2007;156:560-562.
138. Hughes PS. Treatment of lymphomatoid papulosis with imiquimod 5% cream. J Am Acad Dermatol. 2006;54:546-547. (Pubitemid 43243469)
139. Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16:85-89.
140. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
141. Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patientapplied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789-794. (Pubitemid 28216355)
142. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134:25-30. (Pubitemid 28087109)
143. Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns. 1998;5:151.
144. Garcia-Zuazaga J, Cooper KD, Baron ED. Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther. 2005;5:791-800.
145. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56:125-143. (Pubitemid 44969292)
146. Fox FE, Niu Z, Tobia A, et al. Photoactivated hypericin is an antiproliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol. 1998;111:327-332. (Pubitemid 28354724)
147. Schempp CM, Winghofer B, Ludtke R, et al. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol. 2000;142:979-984. (Pubitemid 30304612)
148. Kamuhabwa AR, Roelandts R, de Witte PA. Skin photosensitization with topical hypericin in hairless mice. J Photochem Photobiol B. 1999;53:110-114. (Pubitemid 30047593)
149. Schempp CM, Ludtke R, Winghofer B, et al. Effect of topical application of Hypericum perforatum extract (St. John's wort) on skin sensitivity to solar simulated radiation. Photodermatol Photoimmunol Photomed. 2000;16:125-128. (Pubitemid 30367088)
150. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004;50:363-367. (Pubitemid 38316128)
151. Wolf P, Fink-Puches R, Cerroni L, et al. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol. 1994;31:678-680. (Pubitemid 24309794)
152. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol. 2002;146:178-188. (Pubitemid 34264385)
153. Orenstein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg. 2000;26:765-769.
154. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130:743-751. (Pubitemid 24218666)
155. Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol. 2001;81:184-188. (Pubitemid 32800464)
156. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol. 2001;144:1262-1263. (Pubitemid 34204224)
157. Meisenheimer JL. Treatment of mycosis fungoides using a 308- nm excimer laser: two case studies. Dermatol Online J. 2006;12:11.
158. Nisticò S, Costanzo A, Saraceno R, et al. Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol. 2004;151:877-879. (Pubitemid 39482123)
159. Passeron T, Zakaria W, Ostovari N, et al. Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides. Arch Dermatol. 2004;140:1291-1293. (Pubitemid 39362262)
160. Kontos AP, Kerr HA, Malick F, et al. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed. 2006;22:168-171. (Pubitemid 43805806)
161. Passeron T, Angeli K, Cardot-Leccia N, et al. Treatment of mycosis fungoides by 308 nm excimer laser: a clinical and histological study in 10 patients. Ann Dermatol Venereol. 2007;134: 225-231. (Pubitemid 46524240)
162. Bónis B, Kemény L, Dobozy A, et al. 308 nm UVB excimer laser for psoriasis. Lancet. 1997;350:1522. (Pubitemid 28036564)
163. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol. 2006;24:33-42. (Pubitemid 43112353)